A radiologist's point of view in the presurgical and intraoperative setting of colorectal liver metastases

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Van Cutsem E, Cervantes A, Adam R et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422 (2016). • Of interest
  Medline CASGoogle Scholar
• 2 Avallone A, Piccirillo MC, Aloj L et al. A randomized Phase III study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (optimization of bevacizumab scheduling within chemotherapy scheme). BMC Cancer 16, 69 (2016).
  MedlineGoogle Scholar
• 3 Izzo F, Palaia R, Albino V et al. Hepatocellular carcinoma and liver metastases: clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments. Infect. Agent. Cancer 10, 11 (2015).
  MedlineGoogle Scholar
• 4 Izzo F, Piccirillo M, Palaia R et al. Management of colorectal liver metastases in patients with peritoneal carcinomatosis. J. Surg. Oncol. 100, 345–347 (2009).
  Medline CASGoogle Scholar
• 5 Scaife CL, Curley SA, Izzo F et al. Feasibility of adjuvant hepatic arterial infusion of chemotherapy after radiofrequency ablation with or without resection in patients with hepatic metastases from colorectal cancer. Ann. Surg. Oncol. 10, 348–354 (2003). •• Of considerable interest
  MedlineGoogle Scholar
• 6 Fanotto V, Ongaro E, Rihawi K et al. HER-2 inhibition in gastric and colorectal cancers: tangible achievements, novel acquisitions and future perspectives. Oncotarget 7(42), 69060–69074 (2016).
  MedlineGoogle Scholar
• 7 Rosati G, Cordio S, Aprile G et al. Discontinuation of bevacizumab and FOLFIRI administered up to a maximum of 12 cycles as first-line therapy for metastatic colorectal cancer: a retrospective Italian study. Invest. New Drugs 30, 1978–1983 (2012).
  Medline CASGoogle Scholar
• 8 Catalano O, Sandomenico F, Vallone P et al. Contrast-enhanced ultrasound in the assessment of patients with indeterminate abdominal findings at positron emission tomography imaging. Ultrasound Med. Biol. 42, 2717–2723 (2016).
  MedlineGoogle Scholar
• 9 Granata V, Catalano O, Fusco R et al. The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA ‘uptake’ on the hepatobiliary phase of MR imaging. Abdom. Imaging 40, 2364–2371 (2015).
  MedlineGoogle Scholar
• 10 Petrillo A, Fusco R, Petrillo M et al. Standardized index of shape (SIS): a quantitative DCE-MRI parameter to discriminate responders by non-responders after neoadjuvant therapy in LARC. Eur. Radiol. 25, 1935–1945 (2015).
  MedlineGoogle Scholar
• 11 NCCN clinical practice guidelines in oncology on rectal cancer. Version 2.2015. www.nccn.org.
  Google Scholar
• 12 NCCN clinical practice guidelines in oncology on colon cancer. Version 2.2015. www.nccn.org.
  Google Scholar
• 13 Tirumani SH, Kim KW, Nishino M et al. Update on the role of imaging in management of metastatic colorectal cancer. Radiographics 34, 1908–1928 (2014).
  MedlineGoogle Scholar
• 14 Adam R, De Gramont A, Figueras J et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17, 1225–1239 (2012).
  Medline CASGoogle Scholar
• 15 Khan AZ, Morris-Stiff G, Makuuchi M. Patterns of chemotherapy-induced hepatic injury and their implications for patients undergoing liver resection for colorectal liver metastases. J. Hepatobiliary Pancreat. Surg. 16, 137–1344 (2009).
  MedlineGoogle Scholar
• 16 Granata V, Fusco R, Catalano O et al. Early assessment of colorectal cancer patients with liver metastases treated with antiangiogenic drugs: the role of intravoxel incoherent motion in diffusion-weighted imaging. PLoS ONE 10(11), e0142876 (2015).
  MedlineGoogle Scholar
• 17 Wagner M, Ronot M, Doblas S et al. Assessment of the residual tumour of colorectal liver metastases after chemotherapy: diffusion-weighted MR magnetic resonance imaging in the peripheral and entire tumour. Eur. Radiol. 26(1), 206–215 (2016).
  MedlineGoogle Scholar
• 18 Bernatik T, Strobel D, Hahn EG et al. Detection of liver metastases: comparison of contrast-enhanced wide-band harmonic imaging with conventional ultrasonography. J. Ultrasound Med. 20, 509–515 (2001).
  Medline CASGoogle Scholar
• 19 Campani R, Calliada F, Bottinelli O et al. Improved ultrasound sensitivity in detecting focal liver lesions by B-mode harmonic imaging and contrast enhancement. Radiology 209, 232 (1999).
  Google Scholar
• 20 Dietrich CF, Kratzer W, Strobe D et al. Assessment of metastatic liver disease in patients with primary extrahepatic tumors by contrast-enhanced sonography versus CT and MRI. World J. Gastroenterol. 12, 1699–1705 (2006).
  MedlineGoogle Scholar
• 21 Westwood M, Joore M, Grutters J et al. Contrast-enhanced ultrasound using SonoVue^® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost–effectiveness analysis. Health Technol. Assess. 17, 1–243 (2013).
  Google Scholar
• 22 Kong WT, Ji ZB, Wang WP et al. Evaluation of liver metastases using contrast-enhanced ultrasound: enhancement patterns and influencing factors. Gut. Liver 10, 283–287 (2016).
  MedlineGoogle Scholar
• 23 Quaia E, D'Onofrio M, Palumbo A et al. Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur. Radiol. 16, 1599–1609 (2006).
  MedlineGoogle Scholar
• 24 Piscaglia F, Corradi F, Mancini M et al. Real time contrast enhanced ultrasonography in detection of liver metastases from gastrointestinal cancer. BMC Cancer 7, 171 (2007).
  MedlineGoogle Scholar
• 25 Konopke R, Kersting S, Saeger HD, Bunk A. Detection of liver lesions by contrast-enhanced ultrasound – comparison to intraoperative findings. Ultraschall Med. 26, 107–113 (2005).
  Medline CASGoogle Scholar
• 26 Larsen LP, Rosenkilde M, Christensen H et al. Can contrast-enhanced ultrasonography replace multidetector-computed tomography in the detection of liver metastases from colorectal cancer? Eur. J. Radiol. 69, 308–313 (2009).
  MedlineGoogle Scholar
• 27 Dănilă M, Popescu A, Sirli R et al. Contrast enhanced ultrasound (CEUS) in the evaluation of liver metastases. Med. Ultrason. 12, 233–237 (2010).
  MedlineGoogle Scholar
• 28 D'Onofrio M, Romanini L, Serra C et al. Contrast enhancement ultrasound application infocal liver lesions characterization: a retrospective study about guidelines application (SOCEUS-CEUS survey). J. Ultrasound 19, 199–106 (2015).
  Google Scholar
• 29 Vialle R, Boucebci S, Richer JP et al. Preoperative detection of hepatic metastases from colorectal cancer: prospective comparison of contrast-enhanced ultrasound and multidetector-row computed tomography (MDCT). Diagn. Interv. Imaging 97, 851–855 (2016).
  Medline CASGoogle Scholar
• 30 Scharitzer M, Ba-Ssalamah A, Ringl H et al. Preoperative evaluation of colorectal liver metastases: comparison between gadoxetic acid-enhanced 3.0-T MRI and contrast-enhanced MDCT with histopathological correlation. Eur. Radiol. 23, 2187–2196 (2013).
  Medline CASGoogle Scholar
• 31 Berger-Kulemann V, Schima W, Baroud S et al. Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. Eur. J. Surg. Oncol. 38, 670–676 (2012).
  Medline CASGoogle Scholar
• 32 Kulemann V, Schima W, Tamandl D et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur. J. Radiol. 79, e1–e6 (2011).
  MedlineGoogle Scholar
• 33 Sofue K, Tsurusaki M, Murakami T et al. Does gadoxetic acid-enhanced 3.0T MRI in addition to 64-detector-row contrast-enhanced CT provide better diagnostic performance and change the therapeutic strategy for the preoperative evaluation of colorectal liver metastases? Eur. Radiol. 24, 2532–2539 (2014).
  MedlineGoogle Scholar
• 34 Vriens D, van Laarhoven HW, van Asten JJ et al. Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate. J. Nucl. Med. 50(11), 1777–1784 (2009).
  Medline CASGoogle Scholar
• 35 Granata V, Fusco R, Catalano O et al. Peribiliary liver metastases MR findings. Med. Oncol. 34(7), 124 (2017). •• Of considerable interest
  MedlineGoogle Scholar
• 36 Granata V, Cascella M, Fusco R et al. Immediate adverse reactions to gadolinium-based MR contrast media: a retrospective analysis on 10,608 examinations. Biomed. Res. Int. 3918292 (2016).
  MedlineGoogle Scholar
• 37 Donati F, Boraschi P, Pacciardi F et al. 3T diffusion-weighted MRI in the response assessment of colorectal liver metastases after chemotherapy: correlation between ADC value and histological tumour regression grading. Eur. J. Radiol. 91, 57–65 (2017).
  MedlineGoogle Scholar
• 38 Granata V, Fusco R, Catalano O et al. Intravoxel incoherent motion (IVIM) in diffusion-weighted imaging (DWI) for hepatocellular carcinoma: correlation with histologic grade. Oncotarget 7(48), 79357–79364 (2016).
  MedlineGoogle Scholar
• 39 Chung WS, Kim MJ, Chung YE et al. Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J. Magn. Reson. Imaging 34(2), 345–353 (2011).
  MedlineGoogle Scholar
• 40 Donati OF, Fischer MA, Chuck N et al. Accuracy and confidence of Gd-EOB-DTPA enhanced MRI and diffusion-weighted imaging alone and in combination for the diagnosis of liver metastases. Eur. J. Radiol. 82(5), 822–828 (2013).
  MedlineGoogle Scholar
• 41 Schulz A, Viktil E, Godt JC et al. Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol. 57, 1040–1048 (2016).
  MedlineGoogle Scholar
• 42 Bipat S, van Leeuwen MS, Comans EF et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis e metaanalysis. Radiology 237(1), 123e31 (2005). • Of interest
  Google Scholar
• 43 Shim JR, Lee SD, Han SS et al. Prognostic significance of (18)F-FDG PET/CT in patients with colorectal cancer liver metastases after hepatectomy. Eur. J. Surg. Oncol. 44(5), 670–676 (2018).
  MedlineGoogle Scholar
• 44 Chun YS, Vauthey J-N, Boonsirikamchai P et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302, 2338–2344 (2009).
  Medline CASGoogle Scholar
• 45 D'Alessandro A, Kalayoglu M, Sollinger H et al. The predictive value of donor liver biopsies for the development of primary nonfunction after orthotopic liver transplantation. Transplantation 51, 157–163 (1991).
  MedlineGoogle Scholar
• 46 Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 346, 1221–1231 (2002).
  Medline CASGoogle Scholar
• 47 Kooby DA, Fong Y, Suriawinata A et al. Impact of steatosis on perioperative outcome following hepatic resection. J. Gastrointest. Surg. 7, 1034–1044 (2003).
  MedlineGoogle Scholar
• 48 Laurent A, Nicco C, Chereau C et al. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res. 65, 948–956 (2005).
  Medline CASGoogle Scholar
• 49 Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol. 15, 460–646 (2004).
  Medline CASGoogle Scholar
• 50 Karoui M, Penna C, Amin-Hashem M et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann. Surg. 243, 1–7 (2006).
  MedlineGoogle Scholar
• 51 Julie C, Lutz MP, Aust D et al. Pathological analysis of hepatic injury after oxaliplatin-based neoadjuvant chemotherapy of colorectal cancer liver metastases: results of the EORTC intergroup Phase III study 40983. J. Clin. Oncol. 25 (2007).
  MedlineGoogle Scholar
• 52 Aloia T, Sebagh M, Plasse M et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J. Clin. Oncol. 24, 4983–4990 (2006).
  Medline CASGoogle Scholar
• 53 Malik HZ, Farid S, Al-Mukthar A et al. A critical appraisal of the role of neoadjuvant chemotherapy for colorectal liver metastases: a case–controlled study. Ann. Surg. Oncol. 12, 3519–3526 (2007).
  Google Scholar
• 54 Welsh FK, Tilney HS, Tekkis PP et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br. J. Cancer 96, 1037–1042 (2007).
  Medline CASGoogle Scholar
• 55 Lorenz M, Staib-Sebler E, Gog C et al. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies. Zentralbl. Chir. 128(2), 87–94 (2003).
  MedlineGoogle Scholar
• 56 Kooby DA, Stockman J, Ben-Porat L et al. Influence of transfusions on perioperative and long-term outcome in patients following hepatic resection for colorectal metastases. Ann. Surg. 237, 860–870 (2003).
  MedlineGoogle Scholar
• 57 Granata V, Fusco R, Catalano O et al. Uncommon neoplasms of the biliary tract: radiological findings. Br. J. Radiol. 90(1078), 2016056 (2017).
  Google Scholar
• 58 Arakawa Y, Shimada M, Utsunomya T et al. Oxaliplatin-related sinusoidal obstruction syndrome mimicking metastatic liver tumors. Hepatol. Res. 43, 685–689 (2013).
  MedlineGoogle Scholar
• 59 Alexandrino H, Oliveira D, Cipriano MA et al. Oxaliplatin toxicity presenting as a liver nodule – case report. BMC Cancer 15, 247 (2015).
  MedlineGoogle Scholar
• 60 Schima W, Ba-Ssalamah A, Kurtaran A et al. Post-treatment imaging of liver tumours. Cancer Imaging 7, S28–S36 (2007).
  MedlineGoogle Scholar
• 61 Tirumani SH, Kim KW, Nishino M et al. Update on the role of imaging in management of metastatic colorectal cancer. Radiographics 34, 1908–1928 (2014).
  MedlineGoogle Scholar
• 62 van Kessel CS, Buckens CF, van den Bosch MA et al. Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann. Surg. Oncol. 19, 2805–2813 (2012). • Of interest
  MedlineGoogle Scholar
• 63 Lastoria S, Piccirillo MC, Caracò C et al. Early PET/CT scan is more effective than RECIST in predicting outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab. J. Nucl. Med. 54, 2062–2069 (2013).
  Medline CASGoogle Scholar
• 64 Mertens J, De Bruyne S, Van Damme N et al. Standardized added metabolic activity (SAM) IN ¹⁸F-FDG PET assessment of treatment response in colorectal liver metastases. Eur. J. Nucl. Med. Mol. Imaging 40, 1214–1222 (2013).
  Medline CASGoogle Scholar
• 65 Cai J, Ma H, Huang F et al. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J. Surg. Oncol. 11, 306 (2013).
  MedlineGoogle Scholar
• 66 Cui Y, Zhang XP, Sun YS et al. Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. Radiology 248, 894–900 (2008). • Of interest
  MedlineGoogle Scholar
• 67 Koh DM, Scurr E, Collins D et al. Predicting response of colorectal hepatic metastasis: value of pretreatment apparent diffusion coefficients. AJR Am. J. Roentgenol. 188, 1001–1008 (2007).
  MedlineGoogle Scholar
• 68 Granata V, Fusco R, Reginelli A et al. Radiological assessment of anal cancer: an overview and update. Infect. Agent Cancer 11, 52 (2016).
  MedlineGoogle Scholar
• 69 Devries AF, Griebel J, Kremser C et al. Tumor microcirculation evaluated by dynamic magnetic resonance imaging predicts therapy outcome for primary rectal carcinoma. Cancer Res. 61, 2513–2516 (2001).
  Medline CASGoogle Scholar
• 70 DeVries AF, Kremser C, Hein PA et al. Tumor microcirculation and diffusion predict therapy outcome for primary rectal carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 56, 958–996 (2003).
  MedlineGoogle Scholar
• 71 O'Connor JP, Rose CJ, Jackson A et al. DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6. Br. J. Cancer 105, 139–145 (2011).
  MedlineGoogle Scholar
• 72 De Bruyne S, Van Damme N, Smeets P et al. Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases. Br. J. Cancer 106, 1926–1933 (2012).
  Medline CASGoogle Scholar
• 73 García-Figueiras R, Baleato-González S, Padhani AR et al. Advanced imaging of colorectal cancer: from anatomy to molecular imaging. Insights Imaging 7, 285–309 (2016).
  MedlineGoogle Scholar
• 74 de Graaf W, van Lienden KP, van Gulik TM et al. (99m)Tc-mebrofenin hepatobiliary scintigraphy with SPECT for the assessment of hepatic function and liver functional volume before partial hepatectomy. J. Nucl. Med. 51(2), 229–236 (2010).
  MedlineGoogle Scholar
• 75 de Graaf W, van Lienden KP, Dinant S et al. Assessment of future remnant liver function using hepatobiliary scintigraphy in patients undergoing major liver resection. J. Gastrointest. Surg. 14, 369–378 (2010).
  MedlineGoogle Scholar
• 76 Cieslak KP, Huisman F, Bais T et al. Future remnant liver function as predictive factor for the hypertrophy response after portal vein embolization. Surgery 162(1), 37–47 (2017).
  MedlineGoogle Scholar
• 77 Olthof PB, Tomassini F, Huespe PE et al. Hepatobiliary scintigraphy to evaluate liver function in associating liver partition and portal vein ligation for staged hepatectomy: liver volume overestimates liver function. Surgery 162(4), 775–783 (2017).
  MedlineGoogle Scholar
• 78 Yoshida M, Shiraishi S, Sakamoto F et al. Assessment of hepatic functional regeneration after hepatectomy using (99m)Tc-GSA SPECT/CT fused imaging. Ann. Nucl. Med. 28(8), 780–788 (2014).
  Medline CASGoogle Scholar
• 79 Mitomo, Tsunoda T, Nakamura K, Kuwabara H. Quantification of intrahepatic non-uniform distributions for assessing impaired function of liver using 99Tcm-DTPA-galactosyl serum albumin liver SPECT scintigraphy. Nucl. Med. Commun. 22(5), 505–512 (2001).
  Medline CASGoogle Scholar
• 80 Fukui A, Murase K, Tsuda T et al. Assessment of liver function in chronic liver diseases and regional function of irradiated liver by means of 99mTc-galactosyl-human serum albumin liver scintigraphy and quantitative spectral analysis. Ann. Nucl. Med. 14(6), 467–476 (2000).
  Medline CASGoogle Scholar
• 81 Tsuda N, Okada M, Murakami T. New proposal for the staging of nonalcoholic steatohepatitis: evaluation of liver fibrosis on Gd-EOB-DTPA-enhanced MRI. Eur. J. Radiol. 73, 137–142 (2010).
  MedlineGoogle Scholar
• 82 Planchamp C, Pastor CM, Balant L et al. Quantification of Gd-BOPTA uptake and biliary excretion from dynamic magnetic resonance imaging in rat livers: model validation with 153Gd-BOPTA. Invest. Radiol. 40, 705–714 (2005).
  Medline CASGoogle Scholar
• 83 Tsuda N, Okada M, Murakami T. Potential of gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid (Gd-EOB-DTPA) for differential diagnosis of nonalcoholic steatohepatitis and fatty liver in rats using magnetic resonance imaging. Invest. Radiol. 42, 242–247 (2007).
  Medline CASGoogle Scholar
• 84 Planchamp C, Gex-Fabry M, Becker CD et al. Model-based analysis of Gd-BOPTA-induced MR signal intensity changes in cirrhotic rat livers. Invest. Radiol. 42, 513–521 (2007).
  MedlineGoogle Scholar
• 85 Dahlqvist Leinhard O, Dahlström N, Kihlberg J et al. Quantifying differences in hepatic uptake of the liver specific contrast agents Gd-EOB-DTPA and Gd-BOPTA: a pilot study. Eur. Radiol. 22, 642–653 (2012).
  Medline CASGoogle Scholar
• 86 Tajima T, Takao H, Akai H et al. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging. J. Comput. Assist. Tomogr. 34, 362–366 (2010).
  MedlineGoogle Scholar
• 87 Motosugi U, Ichikawa T, Sou H et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EO B-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J. Magn. Reson. Imaging 30, 1042–1046 (2009).
  MedlineGoogle Scholar
• 88 Tamada T, Ito K, Higaki A et al. Gd-EOB-DTPA-enhanced MR imaging: evaluation of hepatic enhancement effects in normal and cirrhotic livers. Eur. J. Radiol. 80, 311–316 (2011).
  Google Scholar
• 89 Motosugi U, Ichikawa T, Oguri M et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn. Reson. Imaging 29, 1047–1052 (2011).
  Medline CASGoogle Scholar
• 90 Utsunomiya T, Shimada M, Hanaoka J et al. Possible utility of MRI using Gd-EOB-DTPA for estimating liver functional reserve. J. Gastroenterol. 47, 470–476 (2012).
  MedlineGoogle Scholar
• 91 Nishie A, Ushijima Y, Tajima T et al. Quantitative analysis of liver function using superparamagnetic iron oxide- and Gd-EOB-DTPA-enhanced MRI: comparison with Technetium-99m galactosyl serum albumin scintigraphy. Eur. J. Radiol. 81, 1100–1104 (2012).
  MedlineGoogle Scholar
• 92 Watanabe H, Kanematsu M, Goshima S et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging-preliminary observations. Radiology 259, 142–150 (2011).
  MedlineGoogle Scholar
• 93 Katsube T, Okada M, Kumano S et al. Estimation of liver function using T1 mapping on Gd-EOB-DTPA-enhanced magnetic resonance imaging. Invest. Radiol. 46, 277–283 (2011).
  MedlineGoogle Scholar
• 94 Kamimura K, Fukukura Y, Yoneyama T et al. Quantitative evaluation of liver function with T1 relaxation time index on Gd-EOB-DTPA-enhanced MRI: comparison with signal intensity-based indices. J. Magn. Reson. Imaging 40, 884–889 (2014).
  MedlineGoogle Scholar
• 95 Mazzoni G, Napoli A, Mandetta S et al. Intra-operative ultrasound for detection of liver metastases from colorectal cancer. Liver Int. 28, 88–94 (2008).
  MedlineGoogle Scholar
• 96 Ruzzenente A, Conci S, Iacono C et al. Usefulness of contrast-enhanced intraoperative ultrasonography (CE-IOUS) in patients with colorectal liver metastases after preoperative chemotherapy. J. Gastrointest. Surg. 17, 281–287 (2013).
  MedlineGoogle Scholar
• 97 Nanashima A, Tobinaga S, Abo T et al. Usefulness of Sonazoid-ultrasonography during hepatectomy in patients with liver tumors: a preliminary study. J. Surg. Oncol. 103, 152–157 (2011).
  MedlineGoogle Scholar
• 98 Zacherl J, Scheuba C, Imhof M et al. Current value of intraoperative sonography during surgery for hepatic neoplasms. World J. Surg. 26, 550–554 (2002).
  MedlineGoogle Scholar
• 99 Schulz A, Dormagen JB, Drolsum A et al. Impact of contrast-enhanced intraoperative ultrasound on operation strategy in case of colorectal liver metastasis. Acta Radiol. 53, 1081–1087 (2012).
  MedlineGoogle Scholar
• 100 Ferrero A, Langella S, Russolillo N et al. Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J. Gastrointest. Surg. 16, 806–814 (2012).
  MedlineGoogle Scholar
• 101 Conlon R, Jacobs M, Dasgupta D et al. The value of intraoperative ultrasound during hepatic resection compared with improved preoperative magnetic resonance imaging. Eur. J. Ultrasound 16, 211–216 (2003).
  MedlineGoogle Scholar
• 102 D'Onofrio M, Gallotti A, Martone E et al. Is intraoperative ultrasound (IOUS) still useful for the detection of liver metastases? J. Ultrasound 12, 144–147 (2009).
  MedlineGoogle Scholar
• 103 Arita J, Ono Y, Takahashi M et al. Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy. Ann. Surg. Oncol. 21(Suppl. 3), S390–S397 (2014).
  MedlineGoogle Scholar
• 104 Lencioni R. European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) guidelines for the use of contrast agents in liver ultrasound: what is the impact in clinical practice? Eur. Radiol. 15(Suppl. 5), e98–e103 (2005).
  MedlineGoogle Scholar
• 105 Hatanaka K, Kudo M, Minami Y et al. Sonazoid-enhanced ultrasonography for diagnosis of hepatic malignancies: comparison with contrast-enhanced CT. Oncology 75(Suppl. 1), 42–47 (2008).
  MedlineGoogle Scholar
• 106 Nakano H, Ishida Y, Hatakeyama T et al. Contrast-enhanced intraoperative ultrasonography equipped with late Kupffer-phase image obtained by sonazoid in patients with colorectal liver metastases. World J. Gastroenterol. 14, 3207–3211 (2008).
  MedlineGoogle Scholar
• 107 Torzilli G. Contrast-enhanced intraoperative ultrasonography in surgery for liver tumors. Eur. J. Radiol. 51(Suppl.), S25–S29 (2004).
  MedlineGoogle Scholar
• 108 Joo I. The role of intraoperative ultrasonography in the diagnosis and management of focal hepatic lesions. Ultrasonography 34, 246–257 (2015).
  MedlineGoogle Scholar
• 109 Machi J, Uchida S, Sumida K et al. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J. Gastrointest. Surg. 5, 477–489 (2001).
  Medline CASGoogle Scholar
• 110 Razafindratsira T, Isambert M, Evrard S. Complications of intraoperative radiofrequency ablation of liver metastases. HPB (Oxford) 13, 15–23 (2011).
  MedlineGoogle Scholar
• 111 Eng OS, Tsang AT, Moore D et al. Outcomes of microwave ablation for colorectal cancer liver metastases: a single center experience. J. Surg. Oncol. 111, 410–413 (2015).
  MedlineGoogle Scholar
• 112 Meloni MF, Andreano A, Franza E et al. Contrast enhanced ultrasound: should it play a role in immediate evaluation of liver tumors following thermal ablation? Eur. J. Radiol. 81, e897–e902 (2012).
  MedlineGoogle Scholar
• 113 Santambrogio R, Barabino M, Opocher E. Laparoscopic ultrasonography for abdominal tumors. Supplement abstracts of the 11th Congress of the World Federation for Ultrasound in Medicine and Biology, May 28–June 1, 2006, Seoul, Korea. Ultras. Med. Biol. 32(5), 48 (2006).
  Google Scholar
• 114 Rethy A, Langø T, Mårvik R. Laparoscopic ultrasound for hepatocellular carcinoma and colorectal liver metastasis: an overview. Surg. Laparosc. Endosc. Percutan. Tech. 23(2), 135–144 (2013).
  MedlineGoogle Scholar
• 115 Montorsi M, Santambrogio R, Bianchi P et al. Laparoscopy with laparoscopic ultrasound for pretreatment staging of hepatocellular carcinoma: a prospective study. J. Gastrointest. Surg. 5, 312–315 (2001).
  Medline CASGoogle Scholar
• 116 Foroutani A, Garland AM, Berber E et al. Laparoscopic ultrasound vs triphasic computed tomography for detecting liver tumors. Arch. Surg. 135, 933–938 (2000).
  Medline CASGoogle Scholar
• 117 Milsom JW, Jerby BL, Kessler H et al. Prospective, blinded comparison of laparoscopic ultrasonography vs. contrastenhanced computerized tomography for liver assessment in patients undergoing colorectal carcinoma surgery. Dis. Colon Rectum 43, 44–49 (2000).
  Medline CASGoogle Scholar
• 118 de Castro SM, Tilleman EH, Busch OR et al. Diagnostic laparoscopy for primary and secondary liver malignancies: impact of improved imaging and changed criteria for resection. Ann. Surg. Oncol. 11(5), 522–529 (2004).
  Medline CASGoogle Scholar
• 119 Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann. Surg. 230, 309–318 (1999).
  Medline CASGoogle Scholar
• 120 Jarnagin WR, Conlon K, Bodniewicz J et al. A clinical scoring system predicts the yield of diagnostic laparoscopy in patients with potentially resectable hepatic colorectal metastases. Cancer 91, 1121–1128 (2001).
  Medline CASGoogle Scholar
• 121 Dunne DF, Gaughran J, Jones RP et al. Routine staging laparoscopy has no place in the management of colorectal liver metastases. Eur. J. Surg. Oncol. 39(7), 721–725 (2013).
  Medline CASGoogle Scholar